Mar 09, 2022
Immutep Receives Constructive Feedback from US FDA on its Clinical Development Program for EFTI in Metastatic Breast Cancer
Feb 24, 2022
Immutep Appoints Lucy Turnbull as Non-Executive Director
Feb 23, 2022
Immutep to Present at Healthcare Investor Conferences
Feb 17, 2022
Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022
Feb 11, 2022
Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway Inhibitor
